Kanabo
Kanabo · page 3
- Markets & Stocks
EU Cannabis Stocks Review: Board Changes At Kanabo & Cellular Goods, Panaxia Stages Comeback & Akanda Continues Rally
European cannabis stocks had another generally positive week last week, with some major announcements from the North American market prop-up gains across the continent.
- Pharmaceutical
One Year After The First Cannabis Stocks Joined The LSE, Could We See A Fresh Run Of Cannabis IPOs This Year?
FEBRUARY 2022 marked the one-year anniversary of MGC Pharmaceuticals IPO on the London Stock Exchange, which saw cannabis stocks traded on the platform for the first time in its 320-year history.
- Markets & Stocks
EU Cannabis Stocks Review: Stenocare Enters UK, Cellular Goods’ Sales Disappoint & Ukraine Crisis Hammers Stocks
The tragic developments in Ukraine hit global markets hard last week, and cannabis stocks even harder.
- Press releases
Kanabo Buys National UK GP Online Service to Improve Last Mile for Patients
The deal, announced today(MON), is worth £14m. Patients can, for a set price of £39.99, get an appointment with a UK registered GP within half an hour and then get a prescription sent to one of 4,200 pharmacies within an hour for £7.49.
- Press releases
Kanabo Announces Successful Completion of Significant Milestones
Kanabo Group Plc (LSE:KNB) the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers, announces the successful completion of significant milestones set out in the prospectus published on 29 January 2021.
- Press releases
Materia Malta Commences First Sales of Medical Cannabis in Europe
Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D Company that focuses on the distribution of cannabis-derived products for medical patients and wellness CBD consumers, notes that Materia’s wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta“) has commenced sales in Europe of the first medical cannabis flower produced at its EU GMP certified manufacturing site.
- Pharmaceutical
London Stock Exchange Cannabis Company Values Down Almost £200m From Early Peaks
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates for patients and investors alike.
- Press releases
Kanabo Partners With Medocann Group To Develop And Distribute Unique Cannabis Strains And Products For UK And Germany
Kanabo, one of Europe’s fastest-growing medical cannabis R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has signed a partnership agreement with the Medocann Pharma Ltd to develop new products that will target specific medical conditions.
- News
Kanabo Aiming To Build Upon Materia Ventures Brand Following Multi-Million Pound Purchase
KANABO’s proposed share-based purchase of high-profile medical cannabis business Materia Ventures is the ‘perfect match’, says Avihu Tamir, its founder and CEO.
- Pharmaceutical
New Listing Proposals Could Exclude Cannabis Startups From The London Stock Exchange
PROPOSALS to set a minimum valuation level for companies looking to list on the London Stock Exchange could limit the number of cannabis entrants to the market.
- Markets & Stocks
Date Set For First Medical Cannabis Company To List On The London Stock Exchange
THE London Stock Exchange will accept the first cannabis company in its 320-year history next month – marking a significant milestone in the growth and development of the industry in the UK and Europe.
- Policy & Regulation
Cannabis: A Fuel For UK Economic Growth Says Newly-Launched Industry Group
THE UK can ride the global green wave to boost the domestic economy in the post-Covid, post-Brexit world, says a newly formed coalition of senior cannabis players.
